Filter By Category
Archives
Share on -
AVANBULIN
Generic Name: AVANBULIN
ABSTRACT -
Avanbulin (BAL27862) is an investigational small-molecule microtubule/tubulin inhibitor that binds the colchicine site and destabilizes microtubules. Its molecular formula is C₂₀H₁₇N₇O₂. The chemical representation above shows the 2D skeletal structure.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved public dosing regimen is established for routine clinical use unless specifically authorized in a local label.
- Clinical-study dosing, when applicable, is protocol-specific and must not be copied into routine practice.
- Do not administer outside an authorized clinical trial, compassionate-use pathway, or approved product labeling.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Fatigue, nausea, vomiting, diarrhea, or decreased appetite
- Myelosuppression such as neutropenia, anemia, or thrombocytopenia
- Peripheral neuropathy, dizziness, or headache
- Mucositis, infection risk, or laboratory abnormalities
- Infusion or formulation-related reactions may occur in trials
ALLERGIC REACTIONS -
Hypersensitivity to Avanbulin or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avanbulin should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avanbulin may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Other cytotoxic or myelosuppressive therapies may increase toxicity.
- CYP-modulating medicines should be reviewed under trial protocol.
- Vaccines and immunosuppressive medicines require oncology-team guidance.
- Patients should report all medicines, herbal products, and supplements.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Monitor blood counts, neurologic symptoms, and infection signs.
- Use contraception and avoid pregnancy exposure during investigational anticancer therapy.
- Use caution in hepatic, renal, or neurologic impairment as protocol specifies.
- Handle according to cytotoxic-agent precautions where applicable.
WARNINGS –
- Investigational status: safety and effectiveness for routine use may not be established.
- Serious or unexpected adverse events must be managed under protocol and reported promptly.
- Use only by personnel trained for the relevant formulation and administration route.
- Keep out of reach of children.
Share on -
. Developed by